Effect of dietary counseling and dietary fiber on tolerability during weight management with EMP16 and conventional orlistat: a single-blind randomized pilot trial.
التشاور الغذائي وتناول الألياف لتحمّل الجهاز الهضمي أثناء إدارة الوزن باستخدام EMP16 والأورليستات التقليدي: تجربة عشوائية أحادية التعمية (مرحلة 2)
Journal: Scientific reports
University: Unknown
Study Type: RCT
Evidence Level: preliminary
Published:
⚠️ Warning: This is a preliminary study (animal/cell) and has not been proven in humans.
30-Second Summary
Objective: evaluate whether dietary counseling with supplemental fiber improves GI tolerability during dose escalation with EMP16 and conventional orlistat in adults with obesity and prior GI problems. Design: randomized, single-blind, phase 2 pilot comparing EMP16 plus psyllium-based fiber vs conventional orlistat plus maltodextrin placebo for 39 days, with dietary counseling; the primary endpoint is the composite GI tolerability events (GITE) AUC.
1-Minute Summary
Design: randomized, single-blind, phase 2 pilot trial. Population: adults with obesity and prior GI problems. Interventions: EMP16 plus psyllium-based fiber vs conventional orlistat plus maltodextrin placebo, with dietary counseling. Duration: 39 days. Primary endpoint: composite GI tolerability events (GITE) AUC.
3-Minute Summary
Purpose and design: This randomized, single-blind, phase 2 pilot trial investigated whether adding dietary counseling with a psyllium-based fiber supplement could improve GI tolerability during dose escalation with EMP16, a controlled release formulation of orlistat–acarbose, compared with conventional orlistat alone. Participants were adults with obesity (BMI ≥30 kg/m2 or ≥27 kg/m2 with risk factors) who had reported prior GI problems with orlistat or EMP16. They were randomized 1:2 to EMP16 plus psyllium-based fiber or conventional orlistat plus maltodextrin placebo for 39 days, with standardized dietary counseling provided to both groups. The primary endpoint was the composite measure of tolerability events in the GI tract, the GITE AUC, capturing diarrhea, oily spotting, and flatulence, aimed to summarize tolerability across dose escalation. The trial emphasizes pragmatic elements such as counseling and fiber supplementation to reflect real-world weight management conditions. Results are not provided in the abstract, but the authors highlight GITE AUC as the primary outcome, suggesting that fiber co-intervention and counseling may influence GI tolerability during pharmacologic escalation. If signals emerge, this pilot design may justify larger trials to confirm whether psyllium-based fiber could contribute to improved tolerability for therapies with GI adverse effects in adults with obesity and prior GI sensitivity.
Full Analysis
Strengths and design: The study uses a randomized, single-blind design in a clearly defined, treatment-seeking population with obesity and prior GI issues, enhancing relevance to everyday weight-management settings. The primary endpoint, GITE AUC, provides a composite and time-resolved measure of GI tolerability across dose escalation, which can capture multidimensional symptoms rather than a single endpoint. All participants receive dietary counseling, which helps control for dietary confounders and mirrors standard clinical care. The intervention arm combines EMP16 with a psyllium-based fiber supplement, while the control arm uses conventional orlistat with a maltodextrin placebo, enabling an appraisal of whether fiber and counseling might modify tolerability beyond the pharmacologic differences. The short, 39-day duration is appropriate for a phase 2 pilot and allows rapid feasibility assessment, potentially informing larger trials. Limitations: The abstract provides no numerical results, limiting interpretation of tolerability signals. Pilot studies typically have small sample sizes and limited statistical power, and the 1:2 randomization yields unequal group sizes, which can affect precision. The single-blind design raises the possibility of bias in self-reported GI events, particularly when participants may perceive differences in fiber intake or medication. Differences between arms extend beyond fiber; EMP16 and conventional orlistat differ in formulation and dosing, confounding attribution of effects to fiber counseling versus medication. The reliance on self-reported outcomes without objective GI biomarkers, adherence data, or long-term follow up limits generalizability to longer weight management. Despite these caveats, the trial addresses an important question about how nonpharmacologic supports, including dietary counseling and fiber, may complement pharmacotherapy to improve tolerability. If the pilot signals are favorable, larger, longer trials could refine fiber type, dosing, and counseling protocols.Health Implications
If fiber plus dietary counseling shows potential to improve GI tolerability during dose escalation of orlistat-like therapies, daily habits may emphasize including psyllium-based fiber as part of weight-management plans, under clinician guidance. Individuals with prior GI sensitivity might discuss fiber supplementation and structured dietary counseling with care providers. These findings may inform future larger trials to confirm efficacy and safety and to optimize fiber dosing and duration with EMP16 and conventional orlistat. It is important to recognize that tolerability is multifactorial; thus personalized dietary strategies and ongoing monitoring are advisable.
Key Findings
- Primary outcome: GITE AUC score, a composite measure of GI tolerability including diarrhea, oily spotting, and flatulence.
- Study design and arms: randomized, single-blind, phase 2 pilot comparing EMP16 with psyllium-based fiber vs conventional orlistat with maltodextrin placebo over 39 days with dietary counseling.